Watch out, Pfiz­er: Affini­vax lands $226M in fund­ing to ad­vance Pre­vnar 13 ri­val as well as the rest of its pipeline

Affini­vax CEO Steven Brug­ger hit the clin­ic a cou­ple years ago with an un­con­ven­tion­al take on a pneu­mo­coc­cal vac­cine de­signed to de­throne Pfiz­er’s Pre­vnar 13. And now that the can­di­date’s ready for Phase III, Brug­ger has reeled in a $226 mil­lion mega-round to see it through.

The Se­ries C comes sev­er­al months af­ter a $120 mil­lion raise, with Viking Glob­al In­vestors, Bain and Ziff Cap­i­tal Part­ners par­tic­i­pat­ing in both rounds. It’s quite the ac­com­plish­ment for a com­pa­ny that launched with $4 mil­lion in seed fund­ing from the Gates Foun­da­tion back in 2014.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER